Pipeline

At Fibrocor Therapeutics, we are not just treating fibrosis; we put patients first in our drug discovery and clinical development process. Our unwavering commitment to research and innovation has led us to discover the most promising and effective drug candidates in fibrosis treatment, setting us apart as industry leaders.

 

Understanding Kidney Health
Healthy kidneys are remarkable organs that filter waste, regulate blood pressure, and maintain fluid balance in the body. Each kidney contains about one million nephrons working tirelessly to keep us healthy.

Understanding Kidney Disease
Chronic kidney disease affects millions worldwide, causing progressive damage to these vital organs. Visible changes include scarring, cysts, and tissue deterioration that compromise kidney function.

Lead FIB992
Alport Syndrome

First-in-class, highly selective, small molecule kinase inhibitor of a novel target. The target has been validated by multiple academic teams in fibrotic kidney disease models. The target is expressed at low levels in healthy tissues and strongly upregulated in fibrotic conditions. It is a key gate keeper on the matrix stiffness pathway and inhibiting this pathway decreases the secretion of many profibrotic cytokines like TGFβ and CTGF.

The target of FIB992 is well validated for the Alport Syndrome. Both knock-out animals and small molecule inhibitors have shown a decrease of fibrosis and a fast improvement in kidney markers in urine and serum. FIB992 can be the first disease modifying treatment for Alport patients and we aim for approval in 2029.   We have completed GLP-tox and plan to move into the clinic in 2026.

FIB991 is a modulator of the YAP/TAZ, the primary mechanotransduction pathway in fibrotic tissues.  Inhibition of FIB991 blocks the YAP/TAZ pathway, shutting down the activation of fibroblasts and stopping the progression of fibrosis.

FIB991
ADPKD
Kidney Allograft Fibrosis

Our small molecule inhibitors of FIB991 show very strong in vivo anti-fibrotic activities in lung and kidney models. This program is in lead optimization with drug-like properties and close to selection of a pre-clinical candidate.

FIB918

FIB918 is a key protein that promotes fibrosis by playing a critical role in the differentiation and function of myofibroblasts, the cells responsible for scar tissue formation. It is overexpressed in fibrotic diseases in kidneys, liver and lung, where it enhances myofibroblast characteristics like adhesion, contractility, and collagen production.

Because of its central role, FIB918 is a promising therapeutic target for treating fibrotic conditions.  In post kidney transplant patients, the target expression is strongly correlated with increasing fibrosis and decreasing kidney function. Our first-in-class fully human, monoclonal antagonist antibody is ready for GLP-tox.